Advertisement

Systemic Vasculitides

  • Loïc Guillevin
Chapter

Abstract

Vasculitides, a heterogeneous group of illnesses, comprise necrotizing and non-necrotizing inflammatory vessel diseases. Infections are the known causes of some vasculitides, like polyarteritis nodosa (PAN), the consequence of hepatitis virus B (HBV), or mixed cryoglobulinemia, which is induced by hepatitis C virus (HCV). Moreover, other vasculitides might be triggered by other infectious agents. The role of viral infections was incriminated only for some necrotizing vasculitides but not giant-cell vasculitis or other non-necrotizing vasculitides. Research groups mainly looked, unsuccessfully, for viral infections in giant-cell vasculitis, Takayasu’s arteritis, or Behçet’s disease. A bacterial etiology of vasculitis has also been identified, e.g., for syphilis-associated vasculitis or some endocarditis.

Keywords

Vasculitis Viral infection Hepatitis B Hepatitis C Bacterial infection 

Abbreviations

Ab

Antibody

Ag

Antigen

ANCA

Antineutrophil cytoplasmic antibody

HbsAg

Hepatitis B surface antigen

HBV

Hepatitis B virus

HCV

Hepatitis C virus

HIV

Human immunodeficiency virus

PAN

Polyarteritis nodosa

References

  1. 1.
    Trepo C, Thivolet J. Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang. 1970;19(3):410–1.CrossRefPubMedGoogle Scholar
  2. 2.
    Gocke DJ, Hsu K, Morgan C, Bombardieri S, Lockshin M, Christian CL. Association between polyarteritis and Australia antigen. Lancet. 1970;2(7684):1149–53.CrossRefPubMedGoogle Scholar
  3. 3.
    Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992;327(21):1490–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11.CrossRefPubMedGoogle Scholar
  5. 5.
    Scott DG, Bacon PA, Elliott PJ, Tribe CR, Wallington TB. Systemic vasculitis in a district general hospital 1972–1980: clinical and laboratory features, classification and prognosis of 80 cases. Q J Med. 1982;51(203):292–311.PubMedGoogle Scholar
  6. 6.
    McMahon BJ, Bender TR, Templin DW, Maynard JE, Barrett DH, Berquist KR, et al. Vasculitis in Eskimos living in an area hyperendemic for hepatitis B. JAMA. 1980;244(19):2180–2.CrossRefPubMedGoogle Scholar
  7. 7.
    Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R, Gross WL. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum. 2005;53(1):93–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Mahr A, Guillevin L, Poissonnet M, Aymé S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg–Strauss syndrome in a French urban multiethnic population in 2000: a capture–recapture estimate. Arthritis Rheum. 2004;51(1):92–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Guillevin L, Mahr A, Callard P, Godmer P, Pagnoux C, Leray E, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore). 2005;84:313–22.CrossRefGoogle Scholar
  10. 10.
    Henegar C, Pagnoux C, Puéchal X, Zucker JD, Bar-Hen A, Le Guern V, et al. A paradigm of diagnostic criteria for polyarteritis nodosa: analysis of a series of 949 patients with vasculitides. Arthritis Rheum. 2008;58(5):1528–38.CrossRefPubMedGoogle Scholar
  11. 11.
    Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62(2):616–26.CrossRefPubMedGoogle Scholar
  12. 12.
    Darras-Joly C, Lortholary O, Cohen P, Brauner M, Guillevin L. Regressing microaneurysms in 5 cases of hepatitis B virus related polyarteritis nodosa. J Rheumatol. 1995;22(5):876–80.PubMedGoogle Scholar
  13. 13.
    Guillevin L, Lê Thi Huong D, Godeau P, Jaïs P, Wechsler B. Clinical findings and prognosis of polyarteritis nodosa and Churg–Strauss angiitis: a study in 165 patients. Br J Rheumatol. 1988;27(4):258–64.CrossRefPubMedGoogle Scholar
  14. 14.
    Guillevin L, Lhote F, Leon A, Fauvelle F, Vivitski L, Trepo C. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol. 1993;20(2):289–98.PubMedGoogle Scholar
  15. 15.
    Trepo C, Ouzan D, Delmont J, Tremisi J. Superiorité d’un nouveau traitement étiopathogénique curateur des périarterites noueuses induites par le virus de l’hepatite B grâce a l’association corticothérapie brève, vidarabine, échanges plasmatiques. Presse Méd. 1988;17(30):1527–31.PubMedGoogle Scholar
  16. 16.
    Trepo C, Guillevin L. Polyarteritis nodosa and extrahepatic manifestations of HBV infection: the case against autoimmune intervention in pathogenesis. J Autoimmun. 2001;16(3):269–74.CrossRefGoogle Scholar
  17. 17.
    Wartelle-Bladou C, Lafon J, Trepo C, Pichoud C, Picon M, Pellissier JF, et al. Successful combination therapy of polyarteritis nodosa associated with a pre-core promoter mutant hepatitis B virus infection. J Hepatol. 2001;34(5):774–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Guillevin L, Jarrousse B, Lok C, Lhote F, Jaïs JP, Lê Thi Huong D, et al. Longterm followup after treatment of polyarteritis nodosa and Churg–Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol. 1991;18(4):567–74.PubMedGoogle Scholar
  19. 19.
    Guillevin L, Merrouche Y, Gayraud M, Jarrousse B, Royer I, Leon A, et al. Périartérite noueuse du au virus de l’hépatite B. Détermination d’une nouvelle stratégie thérapeutique: 13 cas. Presse Méd. 1988;17(30):1522–6.PubMedGoogle Scholar
  20. 20.
    Guillevin L, Lhote F, Sauvaget F, Deblois P, Rossi F, Levallois D, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis. 1994;53(5):334–7.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Simsek H, Telatar H. Successful treatment of hepatitis B virus-associated polyarteritis nodosa by interferon alpha alone. J Clin Gastroenterol. 1995;20(3):263–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Kruger M, Boker KH, Zeidler H, Manns MP. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b. J Hepatol. 1997;26(4):935–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Auguet T, Barragan P, Ramirez R, Quer JC, Sirvent JJ, Richart C. Lamivudine in the treatment of hepatitis B virus-related polyarteritis nodosa. J Clin Rheumatol. 2007;13(5):298–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Guillevin L, Mahr A, Cohen P, Larroche C, Queyrel V, Loustaud-Ratti V, et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum. 2004;51(3):482–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Erhardt A, Sagir A, Guillevin L, Neuen-Jacob E, Haussinger D. Successful treatment of hepatitis B virus associated polyarteritis nodosa with a combination of prednisolone, alpha-interferon and lamivudine. J Hepatol. 2000;33(4):677–83.CrossRefPubMedGoogle Scholar
  26. 26.
    Wicki J, Olivieri J, Pizzolato G, Sarasin F, Guillevin L, Dayer JM, et al. Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. Rheumatology (Oxford). 1999;38(2):183–5.CrossRefGoogle Scholar
  27. 27.
    Saadoun D, Terrier B, Semoun O, Sene D, Maisonobe T, Musset L, et al. Hepatitis C virus-associated polyarteritis nodosa. Arthritis Care Res (Hoboken). 2011;63(3):427–35.Google Scholar
  28. 28.
    Cacoub P, Lunel-Fabiani F, Du LT. Polyarteritis nodosa and hepatitis C virus infection. Ann Intern Med. 1992;116(7):605–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d’Étude et de Recherche en Médecine Interne et Maladies Infectieuses sur le Virus de l’Hépatite C. Medicine (Baltimore). 2000;79(1):47–56.CrossRefGoogle Scholar
  30. 30.
    Terrier B, Cacoub P. Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol. 2013;25(1):10–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Tarantino A, Campise M, Banfi G, Confalonieri R, Bucci A, Montoli A, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int. 1995;47:618–23.CrossRefPubMedGoogle Scholar
  32. 32.
    Ferri C, Sebastiani M, Giuggioli D, Cazzato M, Longombardo G, Antonelli A, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum. 2004;33(6):355–74.CrossRefPubMedGoogle Scholar
  33. 33.
    Saadoun D, Sellam J, Ghillani-Dalbin P, Crecel R, Piette JC, Cacoub P. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med. 2006;166(19):2101–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Terrier B, Krastinova E, Marie I, Launay D, Lacraz A, Belenotti P, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood. 2012;119(25):5996–6004.CrossRefPubMedGoogle Scholar
  35. 35.
    Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus – associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum. 2006;54(11):3696–706.CrossRefPubMedGoogle Scholar
  36. 36.
    Casato M, Agnello V, Pucillo LP, Knight GB, Leoni M, Del Vecchio S, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood. 1997;90(10):3865–73.PubMedGoogle Scholar
  37. 37.
    Terrier B, Semoun O, Saadoun D, Sene D, Resche-Rigon M, Cacoub P. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum. 2011;63(6):1748–57.CrossRefPubMedGoogle Scholar
  38. 38.
    Cacoub P, Vautier M, Desbois AC, Lafuma A, Saadoun D. Effectiveness and cost of hepatitis C virus cryoglobulinaemia vasculitis treatment: from interferon-based to direct-acting antivirals era. Liver Int. 2017;37(12):1805–13.  https://doi.org/10.1111/liv.13465. Epub 2017 May 29.CrossRefPubMedGoogle Scholar
  39. 39.
    Terrier B, Saadoun D, Sene D, Sellam J, Perard L, Coppere B, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum. 2009;60(8):2531–40.CrossRefPubMedGoogle Scholar
  40. 40.
    Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003;101(10):3827–34.CrossRefPubMedGoogle Scholar
  41. 41.
    Gisselbrecht M, Cohen P, Lortholary O, Jarrousse B, Gayraud M, Gherardi R, et al. HIV-related vasculitis: clinical presentation and therapeutic approach on six patients. AIDS. 1997;11(1):121–3.PubMedGoogle Scholar
  42. 42.
    Guillevin L. Vasculitides in the context of HIV infection. AIDS. 2008;22(Suppl 3):S27–33.CrossRefPubMedGoogle Scholar
  43. 43.
    Golden MP, Hammer SM, Wanke CA, Albrecht MA. Cytomegalovirus vasculitis. Case reports and review of the literature. Medicine (Baltimore). 1994;73(5):246–55.CrossRefGoogle Scholar
  44. 44.
    Krishnamurthy R, Cunningham ET Jr. Atypical presentation of syphilitic uveitis associated with Kyrieleis plaques. Br J Ophthalmol. 2008;92(8):1152–3.CrossRefPubMedGoogle Scholar
  45. 45.
    Frank MW, Mehlman DJ, Tsai F, Lomasney JW, Joob AW. Syphilitic aortitis. Circulation. 1999;100(14):1582–3.CrossRefPubMedGoogle Scholar
  46. 46.
    Gaa J, Weidauer S, Sitzer M, Lanfermann H, Zanella FE. Cerebral vasculitis due to Treponema pallidum infection: MRI and MRA findings. Eur Radiol. 2004;14(4):746–7.CrossRefPubMedGoogle Scholar
  47. 47.
    Giang DW. Central nervous system vasculitis secondary to infections, toxins, and neoplasms. Semin Neurol. 1994;14(4):313–9.CrossRefPubMedGoogle Scholar
  48. 48.
    Koening C, Katz B, Hernandez-Rodriguez J, et al. Identification of a Burkholderia-like strain from temporal arteries of subjects with giant cell arteritis. Arthritis Rheum. 2012;64:S373.Google Scholar
  49. 49.
    Bilge I, Sadikoglu B, Emre S, Sirin A, Aydin K, Tatli B. Central nervous system vasculitis secondary to parvovirus B19 infection in a pediatric renal transplant patient. Pediatr Nephrol. 2005;20(4):529–33.CrossRefPubMedGoogle Scholar
  50. 50.
    Catalano-Pons C, Quartier P, Leruez-Ville M, Kaguelidou F, Gendrel D, Lenoir G, et al. Primary cytomegalovirus infection, atypical Kawasaki disease, and coronary aneurysms in 2 infants. Clin Infect Dis. 2005;41(5):e53–6.CrossRefPubMedGoogle Scholar
  51. 51.
    Leruez-Ville M, Lauge A, Morinet F, Guillevin L, Deny P. Polyarteritis nodosa and parvovirus B19. Lancet. 1994;344(8917):263–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Internal Medicine, Hôpital Cochin, Assistance Publique–Hôpitaux de ParisUniversité Paris DescartesParis Cedex 14France

Personalised recommendations